Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Newron Not Seeing Sarizotan STARS Yet

FDA Calls Meeting To Discuss Rett Drug

Executive Summary

The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.

You may also be interested in...



Acadia, Neuren Headed To Phase III With Trofinetide In Rett Syndrome

Positive Phase II data in the unmet medical need could mean patients will have a therapy specific to their disease, rather than burdensome symptom-by-symptom treatment.

AZ Closer To Second Enhertu OK After Gastric Cancer Success

The Daiichi Sankyo-partnered antibody drug conjugate has just been approved for breast cancer and AstraZeneca's oncology R&D chief tells Scrip that there are many other HER-2-expressing tumor types where Enhertu has shown potential.

J&J's Stelara Gets Europe OK For Pediatric Psoriasis

The European Commission has backed J&J's blockbuster to treat children with psoriasis but the drug has fallen foul of NICE for ulcerative colitis.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141326

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel